United-Guardian Reports First Quarter Results
United-Guardian (NASDAQ:UG) reported Q1 2026 net sales of $2.87M versus $2.48M a year earlier and net income of $818,902 ($0.18/share) versus $560,895 ($0.12/share) in Q1 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
United-Guardian (NASDAQ:UG) reported Q1 2026 net sales of $2.87M versus $2.48M a year earlier and net income of $818,902 ($0.18/share) versus $560,895 ($0.12/share) in Q1 2025. Results included $303,133 settlement income and sales gains in pharmaceuticals and cosmetic ingredients.
Positive
- Net sales +15.8% year-over-year to $2,872,222
- Net income +46.0% year-over-year to $818,902
- $303,133 settlement income recognized in Q1 2026
- Pharmaceutical sales +24% in Q1 2026
- Cosmetic ingredient sales +21% in Q1 2026; ASI purchases +45%
Negative
- Cost of sales increased by 28.9% to $1,447,789
- Total costs and expenses rose by 19.2% to $2,229,773
- Provision for income taxes increased by 45.7% to $214,236
Details
News Market Reaction – UG
On May 8, the day this news came out, UG closed 1.86% below the previous close.
Data tracked by StockTitan Argus for the May 8 session.
Key Figures
- Net sales Q1 2026
- $2,872,222
- Three months ended March 31, 2026
- Net sales Q1 2025
- $2,481,127
- Three months ended March 31, 2025
- Net income Q1 2026
- $818,902
- Three months ended March 31, 2026
- EPS Q1 2026
- $0.18 per share
- Basic and diluted, Q1 2026
- EPS Q1 2025
- $0.12 per share
- Basic and diluted, Q1 2025
- Pharmaceutical sales growth
- 24%
- Pharmaceutical sales increase in Q1 2026 vs Q1 2025
- Cosmetic ingredients growth
- 21%
- Cosmetic ingredient sales increase in Q1 2026 vs Q1 2025
- Settlement income
- $303,133
- Other income in Q1 2026 related to Renacidin contract manufacturer
Previous Earnings Reports
-
FY2025 sales and earnings declined versus 2024 amid cosmetic weakness.
-
Q3 2025 sales and net income fell sharply on reduced ASI orders.
-
Q2 2025 revenue and earnings declined year-over-year despite some sequential gains.
-
Q1 2025 net sales and income dropped, led by cosmetic ingredient weakness.
-
FY2024 delivered double-digit sales and earnings growth across key segments.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
marketable securities financial
forward-looking statements regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAUPPAUGE, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2026. First quarter sales increased from
Donna Vigilante, President of United-Guardian, stated, “I am happy to report that sales and earnings increased in the first quarter of 2026 compared with the first quarter of 2025. Our financial performance was primarily driven by increased sales of both our pharmaceuticals and cosmetic ingredients. Pharmaceutical sales rose by
“In addition to the increase in sales, our income for the quarter was also supplemented by settlement income we recognized from the contract manufacturer (“CM”) of Renacidin in connection with an unexpected shutdown at the CM’s facility in late 2023, which resulted in lost Renacidin sales.”
“With ASI resuming its regular purchasing pattern, new distribution agreements in place, increased emphasis on expanding our “natural” product lines, and our ongoing project to increase outreach and market penetration for Renacidin, we are optimistic that our sales will continue to increase in 2026.”
United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.
| Contact: | Donna Vigilante (631) 273-0900 dvigilante@u-g.com |
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
| FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025 UNITED-GUARDIAN, INC. STATEMENTS OF INCOME (UNAUDITED) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Net sales | $ | 2,872,222 | $ | 2,481,127 | |||
| Costs and expenses: | |||||||
| Cost of sales | 1,447,789 | 1,123,076 | |||||
| Operating expenses | 666,963 | 632,735 | |||||
| Research and development | 115,021 | 114,394 | |||||
| Total costs and expenses | 2,229,773 | 1,870,205 | |||||
| Income from operations | 642,449 | 610,922 | |||||
| Other income: | |||||||
| Investment income | 69,814 | 84,687 | |||||
| Net gain on marketable securities | 17,742 | 12,350 | |||||
| Settlement income | 303,133 | --- | |||||
| Total other income | 390,689 | 97,037 | |||||
| Income before provision for income taxes | 1,033,138 | 707,959 | |||||
| Provision for income taxes | 214,236 | 147,064 | |||||
| Net income | $ | 818,902 | $ | 560,895 | |||
| Earnings per common share (basic and diluted) | $ | 0.18 | $ | 0.12 | |||
| Weighted average shares (basic and diluted) | 4,594,319 | 4,594,319 | |||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.